EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial

Mary B Abraham iD, Grant J Smith, Julie Dart, Antony Clarke, Keely Bebbington, Janice M Fairchild, Geoffrey R Ambler, Fergus J Cameron, Elizabeth A Davis, Timothy W Jones

Diabetes Care · 2025

DOI: 10.2337/dc24-0276 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes Care, 2025. Verfasst von Mary B Abraham und 9 weiteren Autor:innen. Beteiligte Einrichtung: Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, Australia. Hauptthemen laut MEDLINE: Glycated Hemoglobin, Diabetes Mellitus, Type 1, Insulin Infusion Systems, Blood Glucose. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: Medtronic, Special Research Initiative of the Australian Research Council, National Health and Medical Research Council, Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE To determine the efficacy of advanced hybrid closed-loop (AHCL) therapy in a high-risk cohort of youth on continuous subcutaneous insulin infusion (CSII) with or without continuous glucose monitoring (CGM) with suboptimal glycemia. RESEARCH DESIGN AND METHODS In a 6-month multicenter clinical trial, youth with type 1 diabetes with mean and most recent HbA1c >8.5% (65 mmol/mol) were randomly assigned 1:1 to AHCL or treatment as usual (CSII ± CGM). The primary outcome was the 24-week between-group difference in HbA1c. Secondary outcomes included CGM metrics from masked CGM and psychological measures (youth-reported problem areas in diabetes [PAID], quality of life, anxiety, depression, and hypoglycemia fear) assessed using validated questionnaires. RESULTS A total of 42 participants were randomized (mean [SD] age 16.2 [2.5] years, HbA1c 9.8 [1.1]% or 84 [12] mmol/mol, PAID score 50.3 [19.8]). At study end, the mean (SD) HbA1c was 8.8 (1.1)% or 73 (12) mmol/mol with AHCL and 9.9 (1.2)% or 85 (13.1) mmol/mol with CSII ± CGM, with mean adjusted group difference of −0.77% (95% CI −1.45 to −0.09) or −8.4 mmol/mol (−15.8 to −1.0); P = 0.027. AHCL increased time in range 70–180 mg/dL (difference 19.1%; 95% CI 11.1 to 27.1), reduced time >180 mg/dL (difference −17.7%; 95% CI −26.6 to −8.8), with no increase in time spent <70 mg/dL (difference −0.8%; 95% CI −2.7 to 0.6). There was no evidence for difference in psychosocial outcomes between the two groups at study end. CONCLUSIONS AHCL should be encouraged in youth with suboptimal glycemia, as AHCL improves glycemia. However, psychological support remains vital, as technology alone may not be able to reduce the burden of diabetes care in this subgroup.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycated HemoglobinDiabetes Mellitus, Type 1Insulin Infusion SystemsBlood GlucoseHumansAdolescentFemaleMaleBlood Glucose Self-MonitoringInsulinHypoglycemic AgentsQuality of LifeChildYoung AdultTreatment Outcome

Substanzen

Glycated HemoglobinBlood GlucoseInsulinHypoglycemic Agents

Autor:innen und Institutionen

  • Children's Diabetes Centre, Telethon Kids Institute, The University of Western Australia, Perth, Australia.
  • Department of Endocrinology and Diabetes, Perth Children's Hospital, Perth, Australia.
  • Centre for Child Health Research, The University of Western Australia, Perth, Australia.
  • Department of Ophthalmology, Perth Children's Hospital, Perth, Australia.
  • Lions Eye Institute, Centre for Ophthalmology and Visual Sciences, The University of Western Australia, Perth, Australia.
  • Department of Endocrinology and Diabetes, Women's and Children's Hospital, Adelaide, Australia.

ORCID-Profile: Mary B Abraham

Förderung

  • Medtronic
  • Special Research Initiative of the Australian Research Council, National Health and Medical Research Council
  • Roche
  • JDRF
  • Diabetes Clinical Research Network
  • Department of Health/Raine Clinical Research

Zitieren

APA

Abraham, M. B., Smith, G. J., Dart, J., Clarke, A., Bebbington, K., Fairchild, J. M., Ambler, G. R., Cameron, F. J., Davis, E. A., & Jones, T. W. (2025). Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial. Diabetes Care. https://doi.org/10.2337/dc24-0276

Vancouver

Abraham MB, Smith GJ, Dart J, Clarke A, Bebbington K, Fairchild JM, et al. Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial. Diabetes Care. 2025. doi:10.2337/dc24-0276

BibTeX
@article{Abraham2025,
  author = {Abraham, Mary B and Smith, Grant J and Dart, Julie and Clarke, Antony and Bebbington, Keely and Fairchild, Janice M and Ambler, Geoffrey R and Cameron, Fergus J and Davis, Elizabeth A and Jones, Timothy W},
  title = {Glycemic and Psychosocial Outcomes of Advanced Hybrid Closed-Loop Therapy in Youth With High HbA1c: A Randomized Clinical Trial},
  journal = {Diabetes Care},
  year = {2025},
  doi = {10.2337/dc24-0276}
}
Kostenlos starten →